Sigilon Therapeutics, Inc. (SGTX)
| Market Cap | 111.84M |
| Revenue (ttm) | 13.37M |
| Net Income (ttm) | -54.61M |
| Shares Out | 7.23M |
| EPS (ttm) | -7.55 |
| PE Ratio | n/a |
| Forward PE | 7.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $15.47 |
| Previous Close | $15.64 |
| Change ($) | -0.17 |
| Change (%) | -1.09% |
| Day's Open | 15.56 |
| Day's Range | 15.15 - 16.20 |
| Day's Volume | 105,100 |
| 52-Week Range | 14.85 - 54.32 |
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease. It is a rare genetic disorder caused by AGAL deficiency and the accumulation of spe...
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients...
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Li...
About SGTX
Sigilon Therapeutics is a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. We have developed our Shielded Living Therapeutics, or SLTx, platform, which combines advanced cell engineering with cutting-edge innovations in biocompatible materials and enables our product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as p... [Read more...]
| Industry Biotechnology | IPO Date Dec 4, 2020 |
| CEO Rogerio Vivaldi Coelho | Employees 99 |
| Stock Exchange NASDAQ | Ticker Symbol SGTX |
Financial Performance
In 2020, SGTX's revenue was $13.37 million, a decrease of -5.52% compared to the previous year's $14.16 million. Losses were -$54.61 million, 24.3% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 50.25, which is an increase of 224.82% from the latest price.